NCT02294851View on ClinicalTrials.gov

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Intravenously Administered BMS-986168 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Tauopathies
Interventions
DRUG

BMS-986168

DRUG

BMS-986168 Placebo

Trial Locations (2)

75247

Covance Clinical Research Unit Inc., Dallas

90630

WCCT Global, LLC, Cypress

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY

NCT02294851 - A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Intravenously Administered BMS-986168 in Healthy Subjects | Biotech Hunter | Biotech Hunter